Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

6.8K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K
Therapeutic Communication01:30

Therapeutic Communication

8.1K
Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.1K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.1K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.1K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

970
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
970

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus.

Dermatitis : contact, atopic, occupational, drug·2026
Same author

Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.

Advances in therapy·2026
Same author

At-Home High-Intensity Interval Training for Individuals with Paraplegia Following Spinal Cord Injury: A Case Series.

Journal of physical medicine and rehabilitation (Wilmington, Del.)·2026
Same author

Observations on emergence of mannitol-use-deficient <i>Staphylococcus aureus</i>.

Microbiology spectrum·2025
Same author

Patient Values and Preferences in Chronic Urticaria Treatment: A Systematic Review.

JAMA dermatology·2025
Same author

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions.

Allergy·2025
Same journal

Key factors in the diagnosis of sesame allergy in children.

Allergy and asthma proceedings·2026
Same journal

Immunoglobulin E-mediated pumpkin seed allergy in children: Case series and narrative review with a structured literature search.

Allergy and asthma proceedings·2026
Same journal

Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria.

Allergy and asthma proceedings·2026
Same journal

The digital front door: A national analysis of U.S. allergy and immunology fellowship program web sites.

Allergy and asthma proceedings·2026
Same journal

The impact of dietary patterns on the risk of asthma in children.

Allergy and asthma proceedings·2026
Same journal

The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.

Allergy and asthma proceedings·2026
See all related articles

Related Experiment Video

Updated: Feb 3, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K

Severe atopic dermatitis: Therapeutic update.

Chase W Kwon, Lisa A Beck

    Allergy and Asthma Proceedings
    |November 8, 2018
    PubMed
    Summary
    This summary is machine-generated.

    New therapies are emerging for atopic dermatitis (AD), offering hope beyond corticosteroids. Targeted treatments like dupilumab and novel agents in development promise improved management for moderate-to-severe AD patients.

    More Related Videos

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
    14:39

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

    Published on: November 4, 2010

    32.5K
    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
    10:27

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

    Published on: December 15, 2011

    25.0K

    Related Experiment Videos

    Last Updated: Feb 3, 2026

    Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
    06:47

    Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

    Published on: September 27, 2017

    10.2K
    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
    14:39

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

    Published on: November 4, 2010

    32.5K
    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
    10:27

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

    Published on: December 15, 2011

    25.0K

    Area of Science:

    • Dermatology
    • Immunology
    • Pharmacology

    Background:

    • Atopic dermatitis (AD) is a prevalent inflammatory skin condition with significant global health burden.
    • Current systemic treatment options for severe AD have been historically limited, primarily to corticosteroids.
    • Existing therapies often fail to adequately address the needs of patients with moderate-to-severe disease.

    Purpose of the Study:

    • To review new and emerging drug therapies for atopic dermatitis.
    • To highlight advancements in targeted treatments for AD management.
    • To inform healthcare providers about upcoming therapeutic options.

    Main Methods:

    • A nonsystematic review of current literature on AD treatments was performed.
    • Focus was placed on recently approved and investigational drugs.
    • Data on efficacy and safety profiles were considered.

    Main Results:

    • Dupilumab, a monoclonal antibody targeting type 2 cytokines, offers a safe and effective option for moderate-to-severe AD.
    • Numerous novel topical and systemic agents are in clinical development, including Janus kinase (JAK) inhibitors and other immunomodulators.
    • These emerging therapies target key pathways in AD pathogenesis and symptom relief, such as itch.

    Conclusions:

    • The pipeline for AD therapeutics is expanding rapidly with promising new agents.
    • Healthcare providers must stay informed about the efficacy and safety of these novel treatments.
    • Personalized treatment strategies will be crucial for optimizing patient outcomes in AD management.